Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

40.2Gy Versus 49.2Gy Radiotherapy in Low-Risk Target Volume for Chemosensitive Stage II Nasopharyngeal Carcinoma Under Full-Course Immunotherapy: a Multicentre, Randomised, Phase 3 Trial

NCT07328854 is registered in ClinicalTrials.gov with Ming-Yuan Chen as lead sponsor.

NCT NCT07328854
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07328854 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
40.2Gy Versus 49.2Gy Radiotherapy in Low-Risk Target Volume for Chemosensitive Stage II Nasopharyngeal Carcinoma Under Full-Course Immunotherapy: a Multicentre, Randomised, Phase 3 Trial
Lead sponsor
Ming-Yuan Chen
Phase
Phase 3
Overall status
Recruiting
Start date
November 20, 2025
Completion date
June 30, 2032
Enrollment
346 (estimated)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

nasopharyngeal carcinoma